Phase I and pharmacokinetic study of 502U83 (an arylmethylaminopropanediol) in cancer patients

Kit Lam; D. S. Alberts; Y. M. Peng; F. Brodar; B. Matias; M. Modiano; R. Tuttle; V. Sol Lucas; W. Wargin

Phase I and pharmacokinetic study of 502U83 (an arylmethylaminopropanediol) in cancer patients

Kit Lam, D. S. Alberts, Y. M. Peng, F. Brodar, B. Matias, M. Modiano, R. Tuttle, V. Sol Lucas, W. Wargin

Research output: Contribution to journal › Article › peer-review

Abstract

502U83, a novel arylmethylaminopropanediol, has proven active in vivo against a panel of murine leukemia and solid tumors as well as in a tumor clonogenic assay against a variety of fresh human cancers. A total of 35 previously treated cancer patients were enrolled in a phase I study of this compound. The maximally tolerated dose (MTD) appears to be 12800 mg/m²/72 h by continuous intravenous infusion with severe granulocytopenia occurring in three of five patients. There were no objective clinical responses. Serum pharmacokinetic parameters were as follows: plasma terminal phase half-life (t( 1/2 )β) = 3.84 h; total body clearance (CL(B)) = 53.1 l/h/m²; volume of distribution at steady state (V(dss)) = 127.9 l/m²; maximum plasma concentration (C(max)) = 3.7 μg/ml (at 12800 mg/m²/72 h dose).

Original language	English (US)
Pages (from-to)	219-224
Number of pages	6
Journal	Anti-Cancer Drugs
Volume	3
Issue number	3
State	Published - 1992
Externally published	Yes

ASJC Scopus subject areas

Cancer Research
Oncology
Pharmacology

Cite this

@article{2fa21f1dbd6246f6836b6316a0afce86,

title = "Phase I and pharmacokinetic study of 502U83 (an arylmethylaminopropanediol) in cancer patients",

abstract = "502U83, a novel arylmethylaminopropanediol, has proven active in vivo against a panel of murine leukemia and solid tumors as well as in a tumor clonogenic assay against a variety of fresh human cancers. A total of 35 previously treated cancer patients were enrolled in a phase I study of this compound. The maximally tolerated dose (MTD) appears to be 12800 mg/m2/72 h by continuous intravenous infusion with severe granulocytopenia occurring in three of five patients. There were no objective clinical responses. Serum pharmacokinetic parameters were as follows: plasma terminal phase half-life (t( 1/2 )β) = 3.84 h; total body clearance (CL(B)) = 53.1 l/h/m2; volume of distribution at steady state (V(dss)) = 127.9 l/m2; maximum plasma concentration (C(max)) = 3.7 μg/ml (at 12800 mg/m2/72 h dose).",

author = "Kit Lam and Alberts, {D. S.} and Peng, {Y. M.} and F. Brodar and B. Matias and M. Modiano and R. Tuttle and {Sol Lucas}, V. and W. Wargin",

year = "1992",

language = "English (US)",

volume = "3",

pages = "219--224",

journal = "Anti-Cancer Drugs",

issn = "0959-4973",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Phase I and pharmacokinetic study of 502U83 (an arylmethylaminopropanediol) in cancer patients

AU - Lam, Kit

AU - Alberts, D. S.

AU - Peng, Y. M.

AU - Brodar, F.

AU - Matias, B.

AU - Modiano, M.

AU - Tuttle, R.

AU - Sol Lucas, V.

AU - Wargin, W.

PY - 1992

Y1 - 1992

N2 - 502U83, a novel arylmethylaminopropanediol, has proven active in vivo against a panel of murine leukemia and solid tumors as well as in a tumor clonogenic assay against a variety of fresh human cancers. A total of 35 previously treated cancer patients were enrolled in a phase I study of this compound. The maximally tolerated dose (MTD) appears to be 12800 mg/m2/72 h by continuous intravenous infusion with severe granulocytopenia occurring in three of five patients. There were no objective clinical responses. Serum pharmacokinetic parameters were as follows: plasma terminal phase half-life (t( 1/2 )β) = 3.84 h; total body clearance (CL(B)) = 53.1 l/h/m2; volume of distribution at steady state (V(dss)) = 127.9 l/m2; maximum plasma concentration (C(max)) = 3.7 μg/ml (at 12800 mg/m2/72 h dose).

AB - 502U83, a novel arylmethylaminopropanediol, has proven active in vivo against a panel of murine leukemia and solid tumors as well as in a tumor clonogenic assay against a variety of fresh human cancers. A total of 35 previously treated cancer patients were enrolled in a phase I study of this compound. The maximally tolerated dose (MTD) appears to be 12800 mg/m2/72 h by continuous intravenous infusion with severe granulocytopenia occurring in three of five patients. There were no objective clinical responses. Serum pharmacokinetic parameters were as follows: plasma terminal phase half-life (t( 1/2 )β) = 3.84 h; total body clearance (CL(B)) = 53.1 l/h/m2; volume of distribution at steady state (V(dss)) = 127.9 l/m2; maximum plasma concentration (C(max)) = 3.7 μg/ml (at 12800 mg/m2/72 h dose).

UR - http://www.scopus.com/inward/record.url?scp=0026744623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026744623&partnerID=8YFLogxK

M3 - Article

C2 - 1525401

AN - SCOPUS:0026744623

VL - 3

SP - 219

EP - 224

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 3

ER -

Phase I and pharmacokinetic study of 502U83 (an arylmethylaminopropanediol) in cancer patients

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this